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Darunavir (DRV) is one of the most powerful protease inhibitors (PIs) for treating human
immunodeficiency virus type-1 (HIV-1) infection and presents a high genetic barrier to
the generation of resistant viruses. However, DRV-resistant HIV-1 infrequently emerges
from viruses exhibiting resistance to other protease inhibitors. To address this resistance,
researchers have gathered genetic information on DRV resistance. In contrast, few
structural insights into the mechanism underlying DRV resistance are available. To
elucidate this mechanism, we determined the crystal structure of the ligand-free state of
a protease with high-level DRV resistance and six DRV resistance-associated mutations
(including I47V and I50V), which we generated by in vitro selection. This crystal structure
showed a unique curling conformation at the flap regions that was not found in the
previously reported ligand-free protease structures. Molecular dynamics simulations
indicated that the curled flap conformation altered the flap dynamics. These results
suggest that the preference for a unique flap conformation influences DRV binding. These
results provide new structural insights into elucidating the molecular mechanism of DRV
resistance and aid to develop PIs effective against DRV-resistant viruses.
Keywords: Darunavir, HIV-1 protease, drug resistance, crystal structure, flap, I50V, protease inhibitor, molecular
dynamics simulation
INTRODUCTION
At present, more than 20 antiviral drugs are clinically available to treat patients infected
with human immunodeficiency virus type 1 (HIV-1). PIs, such as darunavir (DRV; previously
known as TMC114), suppress HIV-1 replication by inhibiting the functions of the viral protease
(PR). DRV is a second-generation HIV-1 PI and is one of the most potent anti-HIV-1 drugs,
owing to its high antiviral activity and high genetic barrier to the generation of resistant
viruses (Koh et al., 2003; De Meyer et al., 2005; Surleraux et al., 2005; Ghosh et al., 2006;
Dierynck et al., 2007). However, a history of drug-resistant HIV infection and/or experience
of treatment-failure with other regimens could raise concerns about the emergence of DRV-
resistant virus, which subsequently results in incomplete viral suppression (Koh et al., 2010;
Dierynck et al., 2011). The increasing number of these DRV resistance-associated mutations
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at baseline raises the risk of developing DRV resistance
(Delaugerre et al., 2008). The latest International AIDS Society
(IAS)-USA panel list shows 11 mutations associated with DRV
resistance: V11I, V32I, L33F, I47V, I50V, I54M/L, T74P, L76V,
I84V, and L89V (Wensing et al., 2014). The emergence of
DRV-resistant viruses is the most troublesome clinical issue.
The mechanisms underlying DRV resistance must be
elucidated to overcome DRV resistance and develop active drugs
against DRV-resistant viruses. One valuable approach is to obtain
three-dimensional (3D) structure information of PR variants
with high-level resistance to DRV. Nonetheless, few reports have
published 3D structures of PR variants with high-level resistance
to DRV (Saskova et al., 2009; Agniswamy et al., 2012; Zhang
et al., 2014), probably because of the rarity of these PRs. In this
study, we generated viruses with high-level resistance to DRV by
in vitro selection and determined a crystal structure of an HIV-
1 PR with high-level resistance to DRV. We obtained a variant
with high-level resistance to DRV, which carries I47V and I50V
in the PR region. These two mutations are known as the major
DRV-resistance mutations (Wensing et al., 2014), although it has
also been reported that they reduce viral PR activity and viral
fitness (Pazhanisamy et al., 1996; Maguire et al., 2002; Prado
et al., 2002; Liu et al., 2005). The solved high-resolution crystal
structure of the viral PR exhibited a unique curling conformation
at the flap regions (residues 43–58) (Hornak et al., 2006b)
that was not found in the previously reported PR structures.
These results provide new structural insights into elucidating the
TABLE 1 | Twenty multi-drug resistant HIV-1 isolates from clinical samples selected in this study.
Patient ID Exposed PIs Genotypic resistance mutations
Major Minor Other*
FS492 SQV, IDV I54V, V82F, L90M G16E, K20I, I62V, L63P 8
FS796 IDV, NFV M46I, V82F, L90M L63P, H69K 3
FS1041 RTV, NFV V32I, I54V, V82M, L90M K20R, K43T, M36I, I62V, L63P, A71V, G73S 3
FS1120 SQV, RTV I54V, V82S, L90M L10I, L33F, Q58E, L63P, A71V, G73S 2
FS1182 SQV, NFV L90M K20KM, L10I, L63P, A71IV, V77I, G73S 3
FS1673 SQV, RTV, IDV, NFV M46I, I84V, L90M K20KT, I62IV, L63P, A71V, G73S, V77I 7
FS1745 SQV, RTV, IDV, NFV M46I, I84V, L90M L10I, M36I, I62V, L63P, A71T, G73T 7
FS1762 RTV, DV, NFV M46I, I54V, V82A L10I, L24I, L33I, M36L, K43T, I62V, L63P, I64IV 3
FS1777 NFV M46MI, L90LM L10LI, I62V, L63P, A71AV, G73GS, V77I 4
FS2510 SQV, RTV, NFV D30N, M46I, I54V, N88D, L90M L10I, L23I, K43T, I62V, L63P, A71T, V77I 5
FS2628 SQV, RTV, IDV, NFV M46I, I84V, L90M L10I, K20I, M36V, I62V, L63P, A71V, G73S 3
FS2699 RTV, NFV I54V, V82A, L90M L10I, K20I, M36I, A71V, G73S 6
FS2715 IDV, NFV I54V, V82A, L90M L10I, M36V, I62V, L63P, A71V, G73T 2
FS2735 SQV, RTV, IDV, NFV M46MI, I84IV, L90LM L10LI, I62IV, L63P, A71V, G73GS, V77VI 8
FS5929† SQV, RTV, IDV, NFV, APV, LPV M46I, I54V, V82F, L90M L10I, L23I, L33F, F53L, Q58E, I62IV, L63P, A71V, G73S, V77I 3
FS6174 SQV, RTV, NFV D30N, I54V, N88D, L90M L10V, K20T, M36I, I62V, L63T, I64IV, A71V 9
FS6175 SQV, RTV, LPV, ATV V32I, M46L, I54V, V82A, L90M L10V, K20R, M36I, K43KT, F53FL, I62IV, L63P, A71V 4
FS6189 NFV D30N, N88D, L90M L63P, A71I, V77I 4
FS6190 SQV, RTV, NFV, LPV, ATV M46I, I84V, L90M L10I, K20T, M36I, F53L, Q58QE, I62V, L63AT, A71V 8
FS7766 RTV, APV, ATV L90M L10I, L63P, V77I 3
*The column shows the number of PR mutations in each patient other than major and minor mutations.
†The multiple drug-resistant virus sample used in this study to induce DRV-resistant HIV-1.
molecular mechanism of DRV resistance and aid to develop PIs
effective against DRV-resistant viruses.
MATERIALS AND METHODS
Sample Collection
Twenty samples with viral sequences that implied resistance
to multiple drugs were selected from patient samples sent to
the Japanese Drug Resistance HIV-1 Surveillance Network for
regular drug-resistance testing from January 2005 to December
2007 (Table 1; Hattori et al., 2010). This study was conducted
according to the principles of the Declaration of Helsinki. The
Ethical Committee at the National Institute of Infectious Diseases
approved the study. All patients provided written informed
consent for the collection of samples and the subsequent analyses.
In Vitro Selection of a DRV-Resistant Virus
We infected each virus derived from the patient serum into
the R5-MaRBLE cell line (Chiba-Mizutani et al., 2007) and
induced resistance by treating with 2 nMDRV. The cultures were
maintained by changing half of the medium every 3–5 days and
by step-wise increases in the DRV concentration to 1000 nM.
In Vitro Phenotype Assay to Examine Drug
Susceptibility
The susceptibilities to the PIs were evaluated using an in-
house drug susceptibility assay with the R5-MaRBLE cell line as
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described elsewhere (Chiba-Mizutani et al., 2007; Shibata et al.,
2011). Inhibitory concentration 50% (IC50) values were obtained
from three independent experiments.
Extraction and Amplification of Viral RNA
Viral RNA was extracted from the cultured system as follows.
First, virus particles in the cell culture supernatant were collected
by centrifugation at 20,000 × g at 4◦C for 1.5 h. The collected
particles were suspended in 300µL of RNAgents Denaturing
Solution (Promega, Madison, WI, USA). Then, the RNA
was purified by phenol-chloroform extraction. The gag-PR
region (625–3402; positions based on HXB2 numbering) of the
purified RNA was reverse transcribed using a PrimeScript II
High Fidelity One Step RT-PCR Kit (Takara Bio Inc., Kusatsu,
Japan). Subsequently, an inner gag-PR region (681–3348)
was amplified by nested PCR using PrimeSTAR GXL DNA
Polymerase (Takara Bio Inc.). The primer sets used for the
amplification were as follows: reverse transcription PCR, 5′-ATC
TCTAGCAGTGGCGCCCGAACAG and 5′-TACTTCTGT
TAGTGCTTTGGTTCC and nested PCR, 5′-CTCTCTCGA
CGCAGGACTCG and 5′-TAATCCCTGCATAAATCTGAC
TTGC.
Construction of Recombinant Viruses
A DNA fragment of gag-PR region (699–2580) was inserted
into the pNL4-3 clone vector using a GeneArt Seamless
Cloning and Assembly Kit (Thermo Fisher Scientific, Waltham,
MA, USA). First, we amplified the target gag-PR region
with PrimeSTAR GXL Polymerase. The primer set used
for amplification was as follows: 5′-CGGCTTGCTGAAG
CGCGCACAGCAAGAGGCGAGGGGCGGCGACTG and
5′-TTACTGGTACAGTCTCAATAGGACTAATGGG. The
amplified PCR product was ligated with pNL4-3 without
gag-PR.
Construction of the Inactive PR Expression
Vector
The full-length PR region (2253–2549) was amplified by nested
PCR using KOD DNA Polymerase (TOYOBO, Osaka, Japan).
The primer set used for amplification was as follows: 5′-ATAT
ACATATGCCTCAGATCACTCTTTGG and 5′-TGGTGCTCG
AGTTACTAAAAATTTAAAGTGCAGCC. Subsequently, the
PCR product was inserted into pET-41a(+) (Merck Millipore,
Billerica, MA, USA) using NdeI and XhoI restriction enzymes
and a DNA Ligation Kit ver. 2.1 (Takara Bio Inc.). Mutagenesis
was performed to obtain an inactive D25N PR mutant.
FIGURE 1 | The PI susceptibilities of 20 clinical HIV-1 isolates. The
arrows in this figure highlight the results for FS5929. The “fold resistance” in
IC50 are given relative to the IC50 values for the reference wild-type HIV-1
JR-CSF, according to the equation, fold resistance = (the IC50 against a
clinical isolate)/(the IC50 against the JR-CSF).
TABLE 2 | List of PR mutations detected during in vitro selection.
N* DRV resistance mutations Other†
Major† Minor†
47 50 76 11 32 33 89 54 60 62 82
NL4-3 I I L V V L L I D I V
FS5929 (Day 0)‡ – – – – – F – V – V F
FS5929R (Day 154)‡ 4$ V V – I I F V V E – F
3 V V – – I F V V E – F
2 V V – I I F V V E – L
1 V – V I I F V V E – F
1 V – V – I F V V E – F
1 V – – I I F V A E – F
1 V – – I I F V V E – F
*The number of clones with the combination of mutations.
†Classification of the IAS-USA mutation list at June/July 2014.
‡FS5929 and FS5929R denote the input virus for the in vitro selection (day 0) and the virus mixture obtained at the day 154 in this study.
The sequence contains mutations: L10I, L23I, L33F, M46I, F53L, I54V, G57R, Q58E, I62V, L63P, H69R, A71V, G73S, V77I, V82F, L90M, and I93L, compared with NL4-3. L33F is
reported to be associated with DRV-resistance mutations.
$The major virus in the virus mixture obtained at the day 154 (FS5929R) was defined as FS5929R1.
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Expression, Purification, and Refolding of
the Inactive PR
The enzymatically-inactive PR was expressed, purified, and then
refolded by using a method similar to that in the previous report
by Dr. Schiffer’s group (King et al., 2002). Briefly, the inactive
PR was expressed in LB medium with 1mM IPTG at 37◦C. The
inclusion bodies with the PR were collected by using a French
press and subsequently centrifuged at 10,000× g at 4◦C for 5min.
The collected inclusion bodies were washed with 2M urea, and
the PR protein was solubilized in a 50% acetic acid solution. The
obtained PR protein was purified by gel filtration with a HiLoad
26/60 Superdex75 (GE Healthcare Bio-Sciences, Pittsburgh,
PA, USA) and AKTAPrime (GE Healthcare Bio-Sciences). The
PR was refolded in buffer containing sodium acetate (pH
5.5). Finally, the PR was further purified by gel filtration
with a HiLoad 26/60 Superdex75 column (GE Healthcare
Bio-Sciences).
Crystallization of the Inactive PR
The purified PR was concentrated to a final concentration of
2.6mg mL−1 with a VIVASPIN MW5000 concentrator (GE
Healthcare Bio-Sciences). Then, initial crystallization conditions
of PRwere screened using following crystallization screening kits:
Wizard I (Emerald Biosystems, Bainbridge Island, WA, USA),
Wizard II (Emerald Biosystems), and JCSG-plus Screen MD-137
(Molecular Dimensions, Suffolk, UK). The final optimized
crystallization condition after iterative optimization cycles was
at 0.84M Lithium chloride, 0.84mM Sodium citrate, 17%(w/v)
PEG 6000, 10% Glycerol, and 5% Ethylene glycol. The crystal
was obtained by the hanging-drop vapor-diffusion method. The
drops were incubated at 20◦C.
X-ray Diffraction and Data Collection
The X-ray diffraction data were collected at the SPring-8
beamline BL38B1 (Sayo, Hyogo, Japan). The data were integrated
with the HKL2000 program (Otwinowski and Minor, 1997). The
structure of the inactive PR was determined by the molecular
replacement method with the MOLREP programs (Vargin and
Teplyakov, 1997; Winn et al., 2011) using a wild-type (WT) PR
structure (Protein Data Bank (PDB) ID: 1KJ7) (Prabu-Jeyabalan
et al., 2002) as the searchmodel. The structure was further refined
with the REFMAC5 and COOT programs (Murshudov et al.,
1997; Emsley et al., 2010).
Molecular Dynamics (MD) Simulations
We performed 30 ns MD simulations of the ligand-free states of
the PRs under explicit water conditions. The initial structures
of the PRs were generated based on a known crystal structure
(PDB ID: 1HHP) (Spinelli et al., 1991) and the structure solved in
this study. In the initial structures, the PRs were surrounded by
approximately 12,000 water molecules, and N25 was changed to
the catalytically active D25. We conducted energy minimization
for the PR system by first using 10,000 steps of the steepest
descent method and then 10,000 steps of the conjugated gradient
method. We subsequently heated the energy-minimized system
to 310 K (∼37◦C) by using the NVT ensemble. Then, we
performed MD simulations at 310 K and 1 atm by using the
NPT ensemble. During the simulations, hydrogen bonds among
residues in the fireman’s grip, D25/T26/G27/D25′/T26′/G27′,
were retained with a harmonic potential of 100 kcal mol−1 Å−2
and 100 kcal mol−1 degree−2.
We also predicted the structures of mutant PRs in complex
with DRV with 6.0 ns MD simulations by using a method
similar to that in our previous reports (Ode et al., 2007a,b).
Briefly, the initial structure of each molecule was generated
from a crystal structure of PR in complex with DRV (PDB
ID: 1T3R) (Surleraux et al., 2005). We performed 6.0 ns MD
simulations of these structures and then estimated the binding
energies between PR and DRV by the MMPBSA method using
1000 trajectories from the well-equilibrated final 1.0 ns of the
simulations. For the structural comparison, the representative
structure among 1000 snapshots taken during the last 1.0 ns of
the simulations was used. The formation of a hydrogen bond
was defined as described in our previous studies (Ode et al.,
2007a,b).
The simulations were conducted with the AMBER9 software
package (Case et al., 2006). The ff10 force field (Hornak et al.,
2006a) and gaff (Wang et al., 2004) were used to calculate the
energies and forces in the simulations.
RESULTS
In Vitro Selection Yielded Variants that
Accumulated DRV Resistance-Associated
Mutations
To obtain a crystal structure of an HIV-1 PR with high-level
resistance to DRV, we generated a virus with high-level resistance
FIGURE 2 | In vitro selection to induce DRV-resistant viruses. The selection of FS5929 and HIV-1 JR-CSF are indicated with gray dotted and black solid lines,
respectively. The arrow indicates the sampling time point for the collection of FS5929R, which we focused on in this study. The x-axis and y-axis represent “days after
the initial viral infection to cell culture” and “DRV concentration (µM) in cell culture medium,” respectively.
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TABLE 3 | Gag sequence of major DRV-resistant viruses.
Positions* 10 20 30 40 50 60
NL4-3 MGARASVLSG GELDKWEKIR LRPGGKKQYK LKHIVWASRE LERFAVNPGL LETSEGCRQI
FS5929 (Day 0) ---------- ---------- -------K-R ---------- ---------- ----------
FS5929R (Day 154)† ---------- -K-------- -------K-R ---------- ---------- ----------
Positions 70 80 90 100 110 120
NL4-3 LGQLQPSLQT GSEELRSLYN TIAVLYCVHQ RIDVKDTKEA LDKIEEEQNK SKKKAQQAAA
FS5929 (Day 0) ---------- ---------- ---T------ ---------- -E-------- ----------
FS5929R (Day 154) ---------- ---------- ---T------ ---------- -E-------- ----------
Positions 129 139 149 159 169 179
X XXXXXXX
NL4-3 DTGNNS QVS QNYPIVQNLQ GQMVHQAISP RTLNAWVKVV EEKAFSPEVI PMFSALSEGA
FS5929 (Day 0) ------SK-- --F------- ---------- ---------I ---------- ----------
FS5929R (Day 154) ------SK-- --F------- ---------- ---------I ---------- ----------
Positions 189 199 209 219 229 239
NL4-3 TPQDLNTMLN TVGGHQAAMQ MLKETINEEA AEWDRLHPVH AGPIAPGQMR EPRGSDIAGT
FS5929 (Day 0) ---------- ---------- ---------- --------P Q ---------- ---------A
FS5929R (Day 154) ---------- ---------- ---------- --------P Q ---------- ---------A
Positions 249 259 269 279 289 299
NL4-3 TSTLQEQIGW MTHNPPIPVG EIYKRWIILG LNKIVRMYSP TSILDIRQGP KEPFRDYVDR
FS5929 (Day 0) ---------- --S---V--- ---------- ---------- V--------- ----------
FS5929R (Day 154) ---------- --N------- ---------- ---------- V--------- ----------
Positions 309 319 329 339 349 359
NL4-3 FYKTLRAEQA SQEVKNWMTE TLLVQNANPD CKTILKALGP GATLEEMMTA CQGVGGPGHK
FS5929 (Day 0) ---------- ---------- ---------- ---------- A--------- ----------
FS5929R (Day 154) ---------- ---------- ---------- ---------- A--------- ----------
Positions 369 379 389 399 409 419
XXXXXXXX XXXXXX XX
NL4-3 ARVLAEAMSQ VTNPATIMIQ KGNFRNQRKT VKCFNCGKEG HIAKNCRAPR KKGCWKCGKE
FS5929 (Day 0) ---------L --H-----M- ------P--- ---------- -V-R------ -R--------
FS5929R (Day 154) ---------L --H-----M- ------P--- ---------- -V-R------ ----------
Positions 429 439 449 458 456 466
X XXXXXXX XXXXXX XX
NL4-3 GHQMKDCTER QANFLGKIWP SHKGRPGNFL QSRPEPTAP PEESFRFG EETTTPSQKQ
FS5929 (Day 0) -------A-- -IH--E---- ---------- ---A-----P AP-------- ----------
FS5929R (Day 154) ---------- -IH--E---- ---------- ---A-----P AP-------- -K--------
Positions 476
NL4-3 EPIDKELYPL A
FS5929 (Day 0) --M-EG---- -
FS5929R (Day 154) ----EG---- -
FS5929 and FS5929R denote the input viruses for the in vitro selection (day 0) and the virus mixture obtained at the day 154, respectively.
*The eight residues flanking at each of five PR cleavage sites in Gag (MA-CA, CA-p2, p2-NC, NC-p1, and p1-p6) were highlighted with “X.”
†The Gag sequence was shown as a major population sequence.
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TABLE 4 | PI susceptibility assays of recombinant viruses.
NL4-3 rFS5929 rFS5929R1 rFS5929R1I47 rFS5929R1I50 rFS5929R1I47/I50
DRV 0.0057 ± 0.0006* 0.0111 ± 0.0036 (1.9†) >1 (>175.3) >1 (>175.3) 0.5528 ± 0.0722 (96.9) 0.1162 ± 0.0149 (20.4)
APV 0.0278 ± 0.0042 0.4440 ± 0.1263 (16.0) >1 (>35.9) >1 (>35.9) >1 (>35.9) >1 (>35.9)
LPV 0.0182 ± 0.0011 >1 (>54.9) >1 (>54.9) >1 (>54.9) >1 (>54.9) 0.9493 ± 0.0453 (52.1)
RTV 0.0347 ± 0.0049 >1 (>28.8) >1 (>28.8) >1 (>28.8) >1 (>28.8) >1 (28.8)
NFV 0.0120 ± 0.0006 >1 (>83.1) >1 (>83.1) >1 (>83.1) >1 (>83.1) >1 (>83.1)
TPV 0.1368 ± 0.0119 0.0646 ± 0.0192 (0.5) 0.0500 ± 0.0119 (0.4) 0.0204 ± 0.0068 (0.1) 0.2397 ± 0.0250 (1.8) 0.1810 ± 0.0037 (1.3)
ATV 0.0047 ± 0.0013 0.0481 ± 0.0129 (10.2) 0.0178 ± 0.0039 (3.8) 0.0490 ± 0.0109 (10.4) 0.0489 ± 0.0143 (10.4) 0.1350 ± 0.0236 (28.7)
SQV 0.0203 ± 0.0077 0.3030 ± 0.0622 (14.9) 0.2500 ± 0.0506 (12.3) 0.2631 ± 0.0555 (13.0) 0.1838 ± 0.0451 (9.1) 0.2440 ± 0.0183 (12.0)
*IC50 (µM).
†Fold changes from IC50 of HIV-1 NL4-3 are written in parentheses.
FIGURE 3 | Crystal structure of FS5929R1 PR. (A) Ribbon diagram of the PR, which forms a homodimer. The α-helices and β-strands are colored in red and
yellow, respectively. The flap regions (residues 43–58) are highlighted in orange. (B) Locations of mutated residues on the PR. The red, yellow, and green spheres
indicate the locations of the major DRV resistance, minor DRV resistance, and other mutations, respectively, that appeared after the DRV-resistance induction
experiment using FS5929. Mutations that originally existed in FS5929 are shown in gray spheres. (C) Highlighted structure around the flaps in the PR. The mutations
are shown as sticks. The mutations V32I, I47V, and I50V, which appeared during the in vitro selection, are highlighted with red letters. (D) Superposition of our crystal
structures of the PRs (gray) with the crystal structures of the open form [PDB IDs: 2PC0 (cyan), 1TW7 (purple), 4NPU (orange), and 3UF3 (navy)]. (E) Superposition of
our crystal structures of the PRs with a crystal structure of the semi-open form [PDB IDs: 1HHP (green)].
to DRV from a clinically isolated multiple drug-resistant sample
(FS5929). FS5929 contained one minor DRV resistance mutation
(L33F) (Table 2) and conferred the highest DRV resistance (7.7-
fold increase compared with the WT HIV-1 JR-CSF) of the 20
multiple drug-resistant samples selected for this study (Figure 1
and Table 1). After 154 days of culture in the presence of
increasing concentrations of DRV, we obtained a virus mixture
(FS5929R) with high-level resistance to DRV that was viable
in cultures with 1000 nM DRV (Figure 2). Population sequence
analyses of the PR region indicated that FS5929R consisted of
at least seven variants (Table 2). The major virus (referred to as
FS5929R1) had two major DRV resistance mutations (I47V and
I50V), four minor mutations (V11I, V32I, L33F, and L89V), and
V82F. The other minor variants had I47V mutation and either
of I50V or L76V mutation although the other sequences were
similar to that of the major virus. Additionally, we examined
the PR cleavage sites in the gag sequences. No sequence changes
around the cleavage sites occurred during culture (Table 3),
although mutations at the flanking regions of the cleavage sites
were observed in both FS5929 and FS5929R1 (except for the
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TABLE 5 | Crystallographic data collection and refinement statistics.
Parameter Value(s) for HIV-1 PR
DATA COLLECTION
Space group P1
Unit cell dimensions
a (Å) 37.1
b (Å) 48.7
c (Å) 54.2
α (degree) 89.9
β (degree) 74.0
γ (degree) 86.7
Wave length (Å) 1.0
Resolution (Å) 50–1.80 (1.86–1.80)
Rmerge (%) 4.4 (19.4)
Average I/σ (I) 26.9 (3.7)
Completeness (%) 96.0 (92.7)
Multiplicity 1.9 (1.9)
REFINEMENT
Unique reflections 30928
Rwork (%)/Rfree (%) 19.6/24.0
No. of non-H atoms
Protein 3174
Chloride ion 5
Water molecules 142
RMS deviation from ideality
Bonds (Å) 0.019
Angle distance (degree) 2.06
Ramachandran plot
Preferred region (%) 95.2
Allowed region (%) 4.0
Outlier regions (%) 0.8
Average B-factors (Å2)
Main chain 25.3
Side chain 28.0
Solvent 33.9
Values in parentheses correspond to the highest resolution shell. The structure has been
deposited as 5B18 in Protein Data Bank (PDB).
sites between the capsid and p2 and between p1 and p6).
Together, these results show that the high-level DRV resistance
of FS5929R is mainly attributed to the accumulation of DRV
resistance-associated mutations in the PR region. In contrast, no
DRV-resistant virus was developed by the induction of the WT
HIV-1 JR-CSF for over half of a year (Figure 2) as detailed in
previous reports (De Meyer et al., 2005; Surleraux et al., 2005;
Dierynck et al., 2007).
The Major PR Obtained from in vitro
Selection is Resistant to DRV but Not to
TPV
Next, we focused on FS5929R1 and analyzed its resistance to
DRV. We generated recombinant viruses carrying the gag-PR
of FS5929R1 (rFS5929R1) and FS5929 (rFS5929) based on the
HIV-1 NL4-3 backbone. The susceptibility assays showed that
rFS5929R1 displayed a >175-fold increase in DRV resistance
compared with that of WT NL4-3, whereas FS5929 was
susceptible to DRV (1.9-fold increase) (Table 4). We also
constructed three recombinant rFS5929R1 viruses lacking the
major DRV resistance mutations I47V and/or I50V to assess
the contribution of the major mutations to DRV resistance.
Each rFS5929R1 virus without I47V (rFS5929R1I47) and
rFS5929R1 without I50V (rFS5929R1I50) exhibited a >175-fold
and 96.9-fold increase in DRV resistance, respectively, whereas
the rFS5929R1 without the two mutations (rFS5929R1I47/I50)
exhibited a 20.4-fold increase. The results suggest that the two
major mutations, especially I50V, largely contribute to the DRV
resistance in rFS5929R1.
We also measured the resistance to seven other PIs:
amprenavir (APV), lopinavir (LPV), ritonavir (RTV), nelfinavir
(NFV), tipranavir (TPV), atazanavir (ATV), and saquinavir
(SQV). The rFS5929 and rFS5929R1 viruses exhibited 16.0-
and >35.9-fold resistance, respectively, to the DRV-analog
APV. Both viruses exhibited high-level resistance to LPV
(>54.9 fold), RTV (>28.8 fold), and NFV (>83.1 fold).
Interestingly, both viruses were susceptible to TPV (<0.5 fold)
and exhibited 3- to 15-fold resistance to ATV and SQV,
suggesting that the mutations induced by the in vitro selection
with DRV scarcely affected the susceptibilities to TPV, ATV,
and SQV.
Determination of the High-Resolution
Crystal Structure of the Ligand-Free State
of FS5929R1 PR
To investigate the mechanism underlying the DRV resistance
of FS5929R1, we determined the crystal structure of the ligand-
free state of the inactive FS5929R1 PR homodimer at a 1.8 Å
resolution (Figure 3 and Table 5). Our crystal structure had a
conformation similar to that of the open forms (Figure 3D),
as seen in the previous crystal structures of ligand-free PRs
(PDB IDs: 2PC0, 1TW7, 4NPU, and 3UF3; Martin et al., 2005;
Heaslet et al., 2007; Agniswamy et al., 2012; Zhang et al., 2014).
Although two additional PR conformations have been reported
[a semi-open form favored by the ligand-free state of the WT
PR (PDB ID: 1HHP) (Spinelli et al., 1991; Hornak et al., 2006b;
Deng et al., 2011) and a closed form favored by the ligand-
bound state of PR (e.g., PDB ID: 1HVR) (Lam et al., 1994)], few
contacts existed between the flap regions of the two monomers
in our structure, which was in contrast to these semi-open
or closed forms. The root mean squared deviation (RMSD)
values of all Cα atoms in our crystal structure compared with
those in the open-form structures (2PC0, 1TW7, 4NPU, and
3UF3) were 1.36, 1.42, 1.42, and 1.33 Å, respectively (Figure 4).
Contrastingly, the crystal structures of the semi-open and closed
forms (1HHP and 1HVR) showed higher RMSD values (1.62 and
1.76 Å) than for the open-form structures (Figure 3E). Notably,
two of the open-form structures (4NPU and 3UF3) were the
previously reported crystal structures of other PRs with high-
level resistance to DRV, suggesting that PRs with high-level
resistance to DRV commonly favor configurations that resemble
the open form.
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FIGURE 4 | Comparison of the crystal structures of ligand-free PRs; closed-form (PDB ID: 1HVR), semi-open form (1HHP), open form (2PC0, 1TW7,
4NPU, and 3UF3), and the PR purified in this study. (A) RMSD calculations comparing the crystal structures by using the coordinates of the Cα atoms.
(B) Comparison of each Cα atom in the PR structures with the corresponding Cα atom in the FS5929R1 PR.
FIGURE 5 | Flap dynamics in the crystal structure and MD simulations. (A) B factors of the respective residues in the FS5929R1 PR estimated from the crystal
structure and MD simulations. (B) The minimum distance between two flaps in the WT and FS5929R1 PRs calculated with an in-house program. (C) The time course
of the distance between the V50 Cα and the T80 Cα (left, red) or between the V50′ Cα and the T80′ Cα (left, green) and their histogram (center). The black and gray
solid lines indicate the distances in the crystal structure from our study and an open-form structure (PDB ID: 3UF3), respectively. The structural positions of the V50
and T80 Cαs (red) in one monomer and the V50′ and T80′ Cαs in a second monomer are highlighted on the right side of the figure of the PR structure.
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FIGURE 6 | Representative structures of simulations of each PR with DRV. (A) Interactions between PR and DRV. The orange dotted lines indicate hydrogen
bonds. (B) Superposition onto the WT PR structure. Stick representations show important residues in WT (gray), FS5929R1 (purple), and FS5929 PR (blue)
structures. The red arrow indicates the flap region shifted outward in the FS5929R1 PR with DRV.
Our crystal structure had a distinct conformation at the
flap regions and the 80s loops that was absent in the open-
form structures. The flap tip that are around the 50th residue
curled inward in our crystal structure, whereas the 80s loops
were slightly shifted inside of the PR. Therefore, the flap
tips approached the 80s loop within the same monomer.
The distance between the Cα atoms of the 50th and 80th
residues within the same monomer of our crystal structure was
approximately 8.9 Å, whereas the distances were approximately
14.1 and 14.0 Å in the open-form crystal structures (4NPU
and 3UF3, respectively). Interestingly, the regions included the
two major DRV resistance mutations (I47V and I50V) and one
minor mutation (V32I), which were induced by the in vitro
selection (Figure 3C). Hence, the unique curling structure at the
flap regions was likely associated with the DRV resistance of
FS5929R1.
To assess the stability of the unique curling conformation
at the mobile flap regions of the FS5929R1 PR (Figure 5A),
we performed 30.0 ns-timescale MD simulations using
the determined structure as the initial structure. The
MD simulations suggested that the FS5929R1 PR favored
conformations in which the flaps in each monomer were
separated, which was in contrast to the WT PR (Figure 5B
and Supplemental Movies S1, S2). Furthermore, constant
curling at the flap region was observed in one monomer but
not the second monomer (Figure 5C). These observations
suggested that the flap in at least one monomer would frequently
adopt the curling conformation despite the high mobility of
the flap.
Structure Prediction of the FS5929R1 PR in
Complex with DRV
Finally, to evaluate the binding mode of DRV to the FS5929R and
FS5929R1 PRs, we predicted the interactions of both PRs with
DRV, from a crystal structure of the WT PR in complex with
DRV, by MD simulations (Figure 6) as described in our previous
reports (Ode et al., 2007a,b). TheMD simulations indicated that a
flap region of FS5929R1 PR in complex with DRV shifts outward
compared with that of the WT PR in complex with DRV; this
change was not observed in FS5929 PR in complex with DRV.
Furthermore, the FS5929R1 PR could not create direct hydrogen
bonds with the DRV bis-tetrahydrofuran (bis-THF) moiety and
the central hydroxyl group (Figure 7). In contrast, FS5929 PR
could create hydrogen bonds with DRV that were similar to those
of the WT PR despite slight differences in the PR-DRV hydrogen
bond networks between the WT and FS5929 PRs. The binding
energy calculations indicated a 10.9 kcalmol−1 loss of the binding
energy with DRV for each FS5929R1 PR and a 0.8 kcal mol−1 loss
for FS5929 PR compared with the WT PR in complex with DRV.
These results were consistent with the DRV susceptibility results
shown in Table 4, suggesting that the conformational change in
the flap likely affected the binding of DRV to PR.
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FIGURE 7 | Hydrogen bond network between PR and DRV predicted
from MD simulations. The residues in PR and DRV are highlighted with blue
and black, respectively. Hydrogen bonds are represented by dotted lines
colored according to their occurrence during the 5.0–6.0 ns simulations, as
shown in the bottom bar.
DISCUSSION
The virus with high-level resistance to DRV that was generated in
this study (referred to as FS5929R1) harbored 6 DRV resistance-
associated mutations in its PR region. The drug susceptibility
tests with the recombinant virus variants suggested that the
in vitro selection specifically increased the resistance to DRV and
its structural analog APV (Table 4). The two major mutations
(especially I50V) greatly contributed to the resistance of the PR,
which was in agreement with the effects of single substitutions
on the binding of DRV to the WT PR (De Meyer et al., 2006;
Tremblay, 2008).
Notably, the crystal structure of the ligand-free FS5929R1
PR showed an open-form configuration that was similar to
those of the two previously reported ligand-free structures of
PRs with high-level resistance to DRV (PDB IDs: 4NPU and
3UF3). However, the FS5929R1 PR exhibited a unique curling
conformation at the flaps (Figure 3). Because the FS5929R1 PR
harbored the major mutation I50V, which was absent in the other
two PRs, the unique flap conformation is likely attributable to
I50V. The curled flap conformations in the FS5929R1 PR might
hinder the DRV access to the active site of dimeric PR because the
flap tips tended to curl toward the active site. Furthermore, the
unique flap conformation of the FS5929R1 PR would influence
DRV resistance through the change in flexibility of the flap in
the dimeric PR suggested by our MD simulations (Figure 5) and
proposed in previous MD and NMR studies of other PI-resistant
mutants (Perryman et al., 2004; Cai et al., 2012). The high
mobility of the flaps of the FS5929R1 PR would provide little
opportunity for the formation of PI-binding pockets, resulting
in reduced opportunity to bind to DRV. Moreover, when the PR
binds DRV, the high flap mobility coupled with effects of active
site mutations, such as V32I, I47V, and I50V (Kovalevsky et al.,
2006; Liu et al., 2008; Mittal et al., 2013), may result in instability
of the complex due to the expansion of the PI-binding pocket
(Cai et al., 2014; Figure 6).
It is also plausible that the preference for the unique
conformation in FS5929R1 PR would reduce the PR dimerization
inhibition activity of DRV, which is the second inhibitory
mechanism of DRV (Koh et al., 2007, 2011). DRV appears to
bind the region around the 32nd, 33rd, 54th, and 82nd residues
in monomeric PR (Koh et al., 2011; Huang and Caflisch, 2012;
Hayashi et al., 2014). These four residues are positioned close
to the flap tips on the FS5929R1 PR structure. Therefore, the
curling conformation would also shield these residues, resulting
in the inhibition of DRV binding to monomeric PR; in contrast,
the presence of four mutations (V32I, L33F, I54V, and V82F)
in FS5929R1 PR might directly impair the DRV binding to
monomeric PR.
The DRV-resistant FS5929R1 PR remained susceptible to TPV
and exhibited low-to-intermediate resistance to ATV and SQV,
which was similar to the results of previous reports on distinct
DRV-resistant viruses (Dierynck et al., 2007; Saskova et al., 2009;
Rhee et al., 2010). Furthermore, the DRV resistance mutation
I50V was related to hypersusceptibility to TPV (Schapiro et al.,
2010; Bethell et al., 2012), whereas I50V had the potential to
increase susceptibility to ATV (Mittal et al., 2013). Together
with our structural information, this information suggests that
the distinct susceptibilities might be attributed to the strength
of the interactions between the flaps in the PR and these PIs.
Crystal structures of the WT PR with TPV, ATV, and SQV (PDB
IDs: 1D4Y, 2AQU, and 1HXB, respectively) (Krohn et al., 1991;
Thaisrivongs et al., 1996; Clemente et al., 2006) indicate that these
PIs commonly have strong interactions with the flaps, which
differ from the other PIs. TPV has direct interactions with the
main chains of I50 in the flaps, whereas the bulky aromatic
rings in ATV and SQV largely interact with the flaps. DRV
creates water molecule-mediated hydrogen bonds with the flaps.
Therefore, the conformational changes at the flaps may scarcely
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affect the binding of TPV, ATV, and SQV but not DRV. Obtaining
information on the interactions between PR and PIs will aid in
the development of PIs that are more potent than DRV against
PRs with accumulated mutations at the flap.
In conclusion, we identified a novel structural feature that
influences DRV resistance via in vitro selection of HIV-1 variants
with high-level resistance to DRV and subsequent determination
of a crystal structure and a MD simulation of its PR. The
information will aid in the development of potent PIs against
DRV-resistant viruses.
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